Hormonal
Survodutide, a dual glucagon and GLP-1 receptor agonist, produces significant weight loss, BMI reduction, and waist circumference reduction in adults with overweight or obesity.
Survodutide is a once-weekly injection that significantly reduces weight, BMI, and waist size. The benefits are greater with higher doses (>2mg/week) and longer treatment durations (>16 weeks). It is particularly effective for individuals under 50 years old. Common side effects are gastrointestinal, but it offers a non-surgical option for weight management.
The results of this meta-analysis show that Survodutide is effective in reducing weight, BMI and waist circumference, especially with longer interventions and higher doses.
Why this rating
High-quality meta-analysis of randomized controlled trials with a NutriGRADE score of 9, though heterogeneity was high.
Source
Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
Haijun Wan et al. · Diabetology & Metabolic Syndrome · 2024
DOI 10.1186/s13098-024-01501-x
More from this paper
- The efficacy of Survodutide for weight loss is conditional on dose and duration, with doses >2 mg/week and interventions >16 weeks yielding significantly greater reductions in weight and waist circumference.Good
- Younger individuals (≤50 years) experience more significant weight and waist circumference reductions from Survodutide compared to older individuals (>50 years).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →